Company Profile

Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. It offers oncology products, such as Alecensa, Avastin, FoundationOne, Herceptin, Kadcyla, Lunsumio, Perjeta, Phesgo, Polivy, and Tecentriq; Actemra for humanized anti-human IL-6 receptor monoclonal antibody; CellCept, an immunosuppressant; Enspryng, a pH-dependent binding humanized anti-IL-6 receptor monoclonal antibody; Evrysdi, a spinal muscular atrophy agent; Hemlibra, an anti-coagulation factor IXa/X humanized bispecific monoclonal antibody; Mircera, an erythropoiesis-stimulating agent; PiaSky, a pH-dependent binding humanized anti-complement (C5) monoclonal antibody; Tamiflu, an anti-influenza agent; and Vabysmo, an anti VEGF/anti Ang-2 bispecific antibody. The company was formerly known as Chugai Shinyaku Shokai and changed its name to Chugai Pharmaceutical Co., Ltd. in January 1943. The company was founded in 1925 and is headquartered in Chuo, Japan. Chugai Pharmaceutical Co., Ltd. operates as a subsidiary of Roche Holding AG.

Latest News

AU Small Finance Bank Ltd (NSE:AUBANK) Q1 2027 Earnings Call Highlights: Strong Profit and Loan ...

GuruFocus.com • 07/27/2026

IBM Fell 25% as Hardware Spending Dominated AI Budgets. Palantir Sells What Runs on Top.

Motley Fool • 07/27/2026

Dow Jones Futures Rise, Oil Prices Dive On Iran Hopes; Apple Leads Earnings Wave, Fed Meeting Ahead

Investor's Business Daily • 07/27/2026

Kevin Warsh Wanted a ‘Family Feud’ at the Fed; At Wednesday’s Meeting He Might Get One

BeInCrypto • 07/27/2026

China's industrial profit growth moderates as exports cushion uneven recovery

Reuters • 07/27/2026